{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:25:46Z","timestamp":1722889546875},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T00:00:00Z","timestamp":1219276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s10096-008-0589-0","type":"journal-article","created":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T08:57:35Z","timestamp":1219222655000},"page":"83-90","source":"Crossref","is-referenced-by-count":10,"title":["Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany"],"prefix":"10.1007","volume":"28","author":[{"given":"M.","family":"Kresken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brauers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. K.","family":"Geiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Halle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Eiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"German Tigecycline Evaluation Surveillance Trial (G-TEST) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,21]]},"reference":[{"issue":"Suppl 2","key":"589_CR1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF02561661","volume":"27","author":"M Kresken","year":"1999","unstructured":"Kresken M, Hafner D (1999) Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975\u20131995. Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Infection 27(Suppl 2):S2\u2013S8. doi: 10.1007\/BF02561661","journal-title":"Infection"},{"unstructured":"Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA; Studiengruppe (2006) Resistenzsituation bei klinisch wichtigen Infektionserregern gegen\u00fcber Antibiotika in Deutschland und im mitteleurop\u00e4ischen Raum. Bericht \u00fcber die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitspr\u00fcfungen & Resistenz der Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e. V. aus dem Jahre 2004. Antiinfectives Intelligence, Rheinbach, Germany. Available online at: http:\/\/www.p-e-g.org\/ag_resistenz\/PEG-Resistenzstudie%202004.pdf","key":"589_CR2"},{"key":"589_CR3","first-page":"179","volume":"15","author":"M Kresken","year":"2006","unstructured":"Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA; Studiengruppe (2006) Resistenz bei h\u00e4ufig isolierten Enterobacteriaceae gegen\u00fcber Breitspektrum-Antibiotika. Chemother J 15:179\u2013190","journal-title":"Chemother J"},{"key":"589_CR4","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","volume":"43","author":"PJ Petersen","year":"1999","unstructured":"Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT (1999) In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43:738\u2013744","journal-title":"Antimicrob Agents Chemother"},{"key":"589_CR5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/AAC.49.4.1636-1638.2005","volume":"49","author":"AC Fluit","year":"2005","unstructured":"Fluit AC, Florijn A, Verhoef J, Milatovic D (2005) Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 49:1636\u20131638. doi: 10.1128\/AAC.49.4.1636-1638.2005","journal-title":"Antimicrob Agents Chemother"},{"unstructured":"Normenausschuss Medizin (NaMed) im DIN Deutsches Institut f\u00fcr Normung e V. (2004) Empfindlichkeitspr\u00fcfung von Krankheitserregern gegen Chemotherapeutika (DIN 58940). In: DIN Deutsches Institut f\u00fcr Normung e.V. (ed) DIN-Taschenbuch 222, Medizinische Mikrobiologie, Diagnostische Verfahren, 4th edn. Beuth, Berlin, Wien, Z\u00fcrich","key":"589_CR6"},{"key":"589_CR7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1469-0691.2006.01578.x","volume":"12","author":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee","year":"2006","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee (2006) EUCAST technical note on tigecycline. Clin Microbiol Infect 12:1147\u20131149. doi: 10.1111\/j.1469-0691.2006.01578.x","journal-title":"Clin Microbiol Infect"},{"unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2008) Clinical breakpoints. European Society for Clinical Microbiology and Infectious Diseases. Available online at: http:\/\/www.srga.org\/eucastwt\/MICTAB\/index.html","key":"589_CR8"},{"unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2008) Performance standards for antimicrobial susceptibility testing; 18th informational supplement. M100-S18. CLSI, Wayne, PA","key":"589_CR9"},{"key":"589_CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","volume":"52","author":"DJ Hoban","year":"2005","unstructured":"Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group (2005) In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215\u2013227. doi: 10.1016\/j.diagmicrobio.2005.06.001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"589_CR11","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1128\/AAC.00210-06","volume":"50","author":"KB Waites","year":"2006","unstructured":"Waites KB, Duffy LB, Dowzicky MJ (2006) Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 50:3479\u20133484. doi: 10.1128\/AAC.00210-06","journal-title":"Antimicrob Agents Chemother"},{"key":"589_CR12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/jac\/dkn065","volume":"61","author":"G Werner","year":"2008","unstructured":"Werner G, Gfr\u00f6rer S, Fleige C, Witte W, Klare I (2008) Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 61:1182\u20131183. doi: 10.1093\/jac\/dkn065","journal-title":"J Antimicrob Chemother"},{"unstructured":"The European Antimicrobial Resistance Surveillance System (EARSS) (2006) EARSS annual report 2005. EARSS, Bilthoven, The Netherlands. Available online at: http:\/\/www.rivm.nl\/earss\/Images\/EARSS%202005_tcm61-34899.pdf","key":"589_CR13"},{"issue":"Suppl 5","key":"589_CR14","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","volume":"41","author":"PA Bradford","year":"2005","unstructured":"Bradford PA, Weaver-Sands DT, Petersen PJ (2005) In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41(Suppl 5):S315\u2013S332. doi: 10.1086\/431673","journal-title":"Clin Infect Dis"},{"key":"589_CR15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkl514","volume":"59","author":"N Woodford","year":"2007","unstructured":"Woodford N, Hill RLR, Livermore DM (2007) In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 59:582\u2013583. doi: 10.1093\/jac\/dkl514","journal-title":"J Antimicrob Chemother"},{"unstructured":"Wyeth Pharmaceuticals Inc. (2005) Tygacil product insert. Wyeth Pharmaceuticals Inc., Philadelphia, PA. Available online at: http:\/\/www.fda.gov\/cder\/foi\/label\/2005\/021821lbl.pdf","key":"589_CR16"},{"key":"589_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","volume":"56","author":"DM Livermore","year":"2005","unstructured":"Livermore DM (2005) Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 56:611\u2013614. doi: 10.1093\/jac\/dki291","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-008-0589-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-008-0589-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-008-0589-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:34:11Z","timestamp":1559122451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-008-0589-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s10096-008-0589-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2008,8,21]]}}}